Drug Ther Bull. 2001 Sep;39(9):65-8.
Pioglitazone (Actos-Takeda) and rosiglitazone (Avandia-GlaxoSmithKline) belong to a new class of oral antidiabetic medicines (the glitazones or thiazolidinediones). Both are licensed in the UK for "oral combination treatment of type 2 diabetes mellitus in [narrowly defined groups of] patients with insufficient glycaemic control despite maximal tolerated dose of oral monotherapy with either metformin or a sulphonylurea". They are not licensed for use as monotherapy, in combination with insulin, or as part of triple therapy with metformin or a sulphonylurea. What can pioglitazone and rosiglitazone offer in the management of patients with type 2 diabetes?
吡格列酮（艾可拓 - 武田公司）和罗格列酮（文迪雅 - 葛兰素史克公司）属于一类新型口服抗糖尿病药物（格列酮类或噻唑烷二酮类）。在英国，二者均被批准用于“尽管使用了二甲双胍或磺脲类药物的最大耐受口服单药治疗剂量，但血糖控制仍不佳的[狭义定义群体中的]2型糖尿病患者的口服联合治疗”。它们未被批准用于单药治疗、与胰岛素联合使用或作为与二甲双胍或磺脲类药物三联治疗的一部分。吡格列酮和罗格列酮在2型糖尿病患者的管理中能提供什么？
